관상동맥 약물 용출 스텐트 삽입 후 항혈소판제제 3제요법과 2제요법의 임상적 효과 비교
Effect of Triple Compared to Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Percutaneous Coronary Intervention
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
ACC/AHA/SCAI Guideline recommends for administration dual antiplatelet therapy after drug-eluting stent (DES) to prevent restenosis and stent thrombosis in patients with percutaneous coronary intervention (PCI). Recently triple antiplatelet therapy including cilostazol is known to reduce restenosis and stent thrombosis significantly after DES implantation. However, there is lack of data providing the efficacy of triple antiplatelet therapy. The purpose of this study is to evaluate the clinical effects of the triple therapy after DES implantation compared with the dual therapy. This retrospective study collected data from medical charts of 251 patients who received DES implantation between Jul 2006 and Jun 2008. They received either dual antiplatelet therapy (N = 154 clopidogrel and aspirin; Dual group) or triple antiplatelet therapy (N = 97 cliostazol, clopidogrel and aspirin; Triple group). Major adverse cardiac event rates (MACE, included total death, myocardial infarction, target lesion revascularization) at 12 months, 24 months, stent thrombosis, rates of bleeding complications and adverse drug reactions were compared between these two groups. Compared with the dual group, the triple group had a similar incidence of the MACE rates at 24months (12.3% vs. 12.4%, p = 0.99). There is no difference in overall stent thrombosis between two groups (Dual group 2.6% vs. Triple group 4.1%, p = 0.5). Subgroup analysis showed that diabetic patients got more benefit in reducing MACE rates but, there is no statistical difference. Bleeding complications and adverse drug effects were not different significantly. As compared with dual antiplatelet therapy, triple antiplatelet therapy did not reduce the 12-months, 24-months MACE rates and stent thrombosis. Bleeding complications and adverse drug effects were not different.
Abstract
ACC/AHA/SCAI Guideline recommends for administration dual antiplatelet therapy after drug-eluting stent (DES) to prevent restenosis and stent thrombosis in patients with percutaneous coronary intervention (PCI). Recently triple antiplatelet therapy including cilostazol is known to reduce restenosis and stent thrombosis significantly after DES implantation. However, there is lack of data providing the efficacy of triple antiplatelet therapy. The purpose of this study is to evaluate the clinical effects of the triple therapy after DES implantation compared with the dual therapy. This retrospective study collected data from medical charts of 251 patients who received DES implantation between Jul 2006 and Jun 2008. They received either dual antiplatelet therapy (N = 154 clopidogrel and aspirin; Dual group) or triple antiplatelet therapy (N = 97 cliostazol, clopidogrel and aspirin; Triple group). Major adverse cardiac event rates (MACE, included total death, myocardial infarction, target lesion revascularization) at 12 months, 24 months, stent thrombosis, rates of bleeding complications and adverse drug reactions were compared between these two groups. Compared with the dual group, the triple group had a similar incidence of the MACE rates at 24months (12.3% vs. 12.4%, p = 0.99). There is no difference in overall stent thrombosis between two groups (Dual group 2.6% vs. Triple group 4.1%, p = 0.5). Subgroup analysis showed that diabetic patients got more benefit in reducing MACE rates but, there is no statistical difference. Bleeding complications and adverse drug effects were not different significantly. As compared with dual antiplatelet therapy, triple antiplatelet therapy did not reduce the 12-months, 24-months MACE rates and stent thrombosis. Bleeding complications and adverse drug effects were not different.
참고문헌 (29)
- Rosamond W, "Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee", Circulation, 117, pp.e25~e146 (2008)
- Lloyd-Jones D, "Executive Summary: Heart Disease and Stroke Statistics-2010 Update: A Report From the American Heart Association", Circulation, 121, pp.e46~e215 (2010)
- 통계청, "사망원인통계 결과", ~ (2009)
- Serruys PW, "A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease", N Engl J Med, 331, pp.489~495 (1994)
- Fischman D, "A randomized comparison of coronary stent placement and balloon angioplasty in treatment of coronary artery disease", N Engl J Med, 331, pp.496~501 (1994)
- Stettler C, "Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis", Lancet, 370, pp.937~948 (2007)
- Grines CL BR, "Prevention of premature discontinuation of Dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians", Circulation, 115, pp.813~818 (2007)
- Stone GW ES, "Offsetting impact of thrombosis and restenosis on the occurrence of deathand myocardial infarction after paclitaxel-eluting and bare metal stent implantation", Circulation, 115, pp.2842~2847 (2007)
- Kushner F, "2009 Focused Updates: ACC", AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC, SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation, pp.American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol[DOI]
- Snoep JD HM, "Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis", Am Heart J, 154, pp.221~231 (2007)
- Lev EI PR, "Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of Dual drug resistance", J Am Coll Cardiol, 47, pp.27~33 (2006)
- Chen WH, "Aspirin resistance and adverse clinical events in patients with coronary artery disease", Am J Med, 120, pp.631~635 (2007)
- 김장영, "Aspirin and Clopidogrel Resistance in Drug Eluting Stent Era", Korean Circulation Journal, 37(4), pp.135~147 (2007), 대한심장학회
- Douglas Jr J, "Coronary stent restenosis in patients treated with cilostazol", Circulation, 112, pp.2826~2832 (2005)
- Lee S, "Comparison of cilostazol and clopidogrel after successful coronary stenting", Am J Cardiol, 95, pp.859~862 (2005)
- Kim J, "Cilostazol Could Ameliorate Platelet Responsiveness to Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention", CIRCULATION JOURNAL, 71(12), pp.1867~1872 (2007), JAPANESE CIRCULATION SOCIETY
- Tsuchikane E, "Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty", Circulation, 100, pp.21~26 (1999)
- Lee S, "Triple Versus Dual Antiplatelet Therapy After Coronary Stenting: Impact on Stent Thrombosis", J Am Coll Cardiol, 46, pp.1833~1837 (2005)
- Lee S, "Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients With Diabetes Mellitus: The DECLAREDIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy With Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients)", J Am Coll Cardiol, 51, pp.1181~1187 (2008)
- Spaulding C, "A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents", N Engl J Med, 356, pp.989~997 (2007)
- Chesebro J, "Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge", Circulation, 76, pp.142~154 (1987)
- Gawaz M, "Platelet function in acute myocardial infarction treated with direct angioplasty", Circulation, 93, pp.229~237 (1996)
- Park D, "Frequency of and risk factors forstent thrombosis after drug-eluting stent implantation during long-term follow-up", Am J Cardiol, 98, pp.352~356 (2006)
- Park S, "Comparison of cilostazol versus ticlopidine therapy after stent implantation", Am J Cardiol, 84, pp.511~514 (1999)
- Lee S, "Comparison of Triple versus Duala ntiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial)", Am J Cardiol, 100, pp.1103~1108 (2007)
- Chen K, "Triple Versus Dual Antiplatelet Therapy in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention", Circulation, 119(25), pp.3207~3214
- 박근호, "Efficacy of Triple Anti-Platelet Therapy Including Cilostazol in Acute Myocardial Infarction Patients Undergoing Drug-Eluting Stent Implantation", Korean Circulation Journal, 39(5), pp.190~197 (2009), 대한심장학회
- 금동성, "약물용출 스텐트 삽입 후 추가적 Cilostazol 투여의 임상적 효과", Korean Circulation Journal, 39(1), pp.21~25 (2009), 대한심장학회